Abstract
The purpose of this study was to demonstrate the relationship between serum uric acid level and major adverse cardiovascular events during admission and 30-day period after admission across the whole spectrum of acute coronary syndrome (ACS).Total 176 patients with new onset ACS were included in the study. Patients with prior history of coronary artery disease, chronic liver or kidney disease, any malignancy and patients on drugs affecting serum uric acid levels were excluded. Routine laboratory investigations, resting 12 lead ECG and ECHO cardiography were done for all patients. Serum uric acid (SUA) was obtained within 24 hours of admission. The patients were divided into two groups: Group I: 41 patients with elevated serum uric acid (>8.2 mg/dl in males and >6.1 mg/dl in females); Group II: 135 patients with normal serum uric acid levels. We monitored the patients in the hospital and followed the patients for 30 days for the occurrence of major adverse cardiovascular events (MACE). The incidence of MACE and mortality were significantly higher in patients with hyperuricemia than in patients with normal serum uric acid during hospital stay and 30 days follow-up (p<0.05). There was a statistically significant correlation between high serum uric acid level and higher Killip class on day of admission. Multivariate logistic regression analysis of data showed a significant difference between group I and II, confirming that SUA can be utilised as a useful biomarker for predicting short-term mortality and MACE in patients with ACS.
References
- Mendis, S.,Puska, P. & Norrving, B. (Eds) Global Atlas on Cardiovascular Disease Prevention and Control (WHO, 2011)
- Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation1999; 99:1671–7.
- Castelli P, Condemi AM, Brambillasca C, Fundaro P, Botta M, Lemma M, et al. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 1995; 25: 119-25.
- Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S. Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology 2009; 114:300–5.
- Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, et al. Prognostic usefulness of serum uric acid after myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005;96: 489-95
- Homayounfar S, Ansari M, Kashani KM. Evaluation of independent prognostic importance of hyperuricemia in hospital death after acute myocardial infarction. Saudi Med J 2007; 28(5):759–61
- Chen L, Li X, Qiao W, Ying Z, Qin Y, Wang Y,et al. Serum uric acid in patients with acute ST-elevation myocardial infarction.World Journal of Emergency Medicine. 2012;3(1):35-9
- Kowalczyk J, Francuz P, Swoboda R, Lenarczyk R, Sredniawa B, Golda A, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron ClinPract 2010;116:c114–22
- Bae MH, Lee JH, Lee SH, Park SH, Yang DH, Park HS, et al. Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal pro-B-type natriuretic peptide in patients with acute myocardial infarction. Circ J 2011; 75: 1440-77
- Ndrepapa G, Braun S, Haase HU, Schulz S, Ranftl S, Hadamitzky M, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J cardiol2012;109:1260-5.
Corresponding Author
Dr Mahak Garg
4054, Whispering Villas, Sector 125, Sunny Enclave, Mohali, Punjab, India
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mob. 9805156541
DOI: https://dx.doi.org/10.18535/jmscr/v6i5.55
